Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 10/20 | 0.50 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064173 | 0.89 | QPCT (0.48) | QPCTNAMPTEPHX1NPC1RAB9A | |
| SCHEMBL27548487 | 0.77 | NPC1 (0.55) | QPCTNAMPTEPHX1NPC1RAB9A | |
| SCHEMBL13373434 | 0.75 | QPCT (0.53) | QPCTNAMPTEPHX1NPC1RAB9A | |
| SCHEMBL3635986 | 0.75 | QPCT (0.84) | QPCTNPC1RAB9A | |
| SCHEMBL3632643 | 0.75 | QPCT (0.84) | QPCTNPC1RAB9A | |
| SCHEMBL13373368 | 0.72 | QPCT (0.50) | QPCTNAMPTEPHX1NPC1RAB9A | |
| SCHEMBL3633558 | 0.71 | QPCT (0.83) | QPCTNPC1RAB9APOLB | |
| SCHEMBL5265934 | 0.71 | NAMPT (0.51) | QPCTNAMPTEPHX1NPC1RAB9A | |
| SCHEMBL13373496 | 0.71 | RAB9A (0.62) | NAMPTNPC1RAB9APOLB | |
| SCHEMBL13373422 | 0.70 | NAMPT (0.81) | QPCTNAMPTNPC1RAB9AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCT 3/4885NAMPT 1137/4885EPHX1 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.